Novalgin (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, decreasing prostaglandin production. This reduces pain signaling and fever, while also providing a spasmolytic effect on smooth muscle, helping to relieve visceral pain.

The dose of Novalgin is determined by the prescribing clinician based on the patient’s condition, age, weight, and response. It is administered by intramuscular or intravenous injection under medical supervision.

The safety of metamizole sodium in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To order Novalgin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Novalgin (metamizole sodium) belongs to the pyrazolone class, offering strong analgesic and antipyretic effects with a spasmolytic component. Compared with NSAIDs, it has a lower risk of gastrointestinal irritation but carries a rare risk of agranulocytosis. It is distinct from opioid analgesics, which act on opioid receptors and have different side‑effect profiles.

Novalgin should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly sealed to maintain sterility.

Novalgin is administered by a healthcare professional via intramuscular or intravenous injection. The route, injection site, and rate of administration are determined by the prescriber based on the clinical situation.

The most serious risks include agranulocytosis, a severe reduction in white blood cells that can lead to life‑threatening infections, and rare allergic reactions such as anaphylaxis or severe skin disorders like Stevens‑Johnson syndrome. Immediate medical attention is required if these symptoms occur.

Novalgin should not be used by patients with a known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis or severe blood dyscrasias, and it is contraindicated in individuals for whom the risk outweighs the benefit as assessed by a qualified clinician.